van den Bosch Wytse B, Ruijgrok Elisabeth J, Tousi Navid M, Tiddens Harm A W M, Janssens Hettie M
Department of Pediatrics, Division of Respiratory Medicine and Allergy, Erasmus MC-Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Department of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
J Aerosol Med Pulm Drug Deliv. 2024 Dec;37(6):351-361. doi: 10.1089/jamp.2024.0005. Epub 2024 Sep 4.
Small airways disease (SAD) in severe asthma (SA) is associated with high disease burden. Effective treatment of SAD could improve disease control. Reduced end-expiratory flows (forced expiratory flow [FEF] and FEF) are considered sensitive indicators of SAD. Inhaled medication should be delivered to the smaller peripheral airways to treat SAD effectively. Aerosol deposition is affected by structural airway changes. Little is known about the effect of SAD on aerosol delivery to the smaller peripheral airways. Functional respiratory imaging (FRI) is a validated technique using 3D reconstructed chest computed tomography (CT) and computational fluid dynamics to predict aerosol deposition in the airways. This study aims to compare central and peripheral (= small airways) deposition between children with SA and SAD and children with SA without SAD, with different inhaler devices and inhalation profiles. FRI was used to predict the deposition of beclomethasone/formoterol dry powder inhaler (DPI), beclomethasone/formoterol pressurized metered dose inhaler with valved holding chamber (pMDI/VHC), and salbutamol pMDI/VHC for different device-specific inhalation profiles in chest-CT of 20 children with SA (10 with and 10 without SAD). SAD was defined as FEF and FEF z-score < -1.645 and forced vital capacity (FVC) z-score > -1.645. No SAD was defined as forced expiratory volume (FEV), FEF, FEF, and FVC z-score > -1.645. The intrathoracic, central, and peripheral airways depositions were determined. Primary outcome was difference in central-to-peripheral (C:P) deposition ratio between children with SAD and without SAD. Central deposition was significantly higher (∼3.5%) and peripheral deposition was lower (2.9%) for all inhaler devices and inhalation profiles in children with SAD compared with children without SAD. As a result C:P ratios were significantly higher for all inhaler devices and inhalation profiles, except for beclomethasone administered through DPI ( = .073), in children with SAD compared with children without SAD. Children with SA and SAD have higher C:P ratios, that is, higher central and lower peripheral aerosol deposition, than children without SAD. The intrathoracic, central, and peripheral deposition of beclomethasone/formoterol using DPI was lower than using pMDI/VHC.
重度哮喘(SA)中的小气道疾病(SAD)与高疾病负担相关。有效治疗SAD可改善疾病控制。呼气末流量降低(用力呼气流量[FEF]和FEF)被认为是SAD的敏感指标。吸入药物应送达较小的外周气道以有效治疗SAD。气溶胶沉积受气道结构变化影响。关于SAD对气溶胶输送至较小外周气道的影响知之甚少。功能性呼吸成像(FRI)是一种经过验证的技术,使用三维重建胸部计算机断层扫描(CT)和计算流体动力学来预测气道中的气溶胶沉积。本研究旨在比较患有SA和SAD的儿童与未患有SAD的SA儿童之间,使用不同吸入装置和吸入模式时,中央气道和外周气道(即小气道)的沉积情况。FRI用于预测20名SA儿童(10名患有SAD,10名未患有SAD)胸部CT中不同装置特定吸入模式下,倍氯米松/福莫特罗干粉吸入器(DPI)、带储雾罐的倍氯米松/福莫特罗压力定量吸入器(pMDI/VHC)和沙丁胺醇pMDI/VHC的沉积情况。SAD定义为FEF和FEF z评分<-1.645且用力肺活量(FVC)z评分>-1.645。无SAD定义为第一秒用力呼气容积(FEV)、FEF、FEF和FVC z评分>-1.645。确定胸腔内、中央气道和外周气道的沉积情况。主要结局是患有SAD和未患有SAD的儿童之间中央与外周(C:P)沉积率的差异。与未患有SAD的儿童相比,患有SAD的儿童在所有吸入装置和吸入模式下,中央沉积显著更高(约3.5%),外周沉积更低(2.9%)。因此,与未患有SAD的儿童相比,患有SAD的儿童在所有吸入装置和吸入模式下,除了通过DPI给药的倍氯米松(P = 0.073)外,C:P比率显著更高。与未患有SAD的儿童相比,患有SA和SAD的儿童具有更高的C:P比率,即更高的中央气道气溶胶沉积和更低的外周气道气溶胶沉积。使用DPI时,倍氯米松/福莫特罗的胸腔内、中央气道和外周气道沉积低于使用pMDI/VHC时。